NeuroDerm

Focus: NeuroDerm is an Israeli biotech founded in 2021 focused on reformulations of established drugs, primarily targeting Parkinson's Disease through novel delivery mechanisms. The company operates as a pre-revenue stage biotech with a concentrated pipeline in neurology.

Neurology

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Open Jobs

About NeuroDerm

AI assessmentNot Hiring

No open roles listed right now. Follow NeuroDerm to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Levodopa/Carbidopa

Parkinson's Disease

Phase 1

ND0612

Parkinson's Disease

Phase 1

Clinical Trials (1)

Help build intelligence for NeuroDerm

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work on Phase 3 assets (ND0612) with clear regulatory pathway in large Parkinson's market
Reformulation strategy reduces molecule risk vs. de novo drug discovery, focusing on delivery innovation
Early-stage biotech offers equity upside and cross-functional impact during critical development phases

Watch Out For

Currently zero open job listings—hiring appears frozen or severely limited
Pre-revenue stage with undisclosed funding raises questions about cash runway and financial stability
Focused pipeline (Parkinson's dominant) limits career diversification across therapeutic areas

Generated by Claude from NeuroDerm's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NCT01486628Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers

Phase 1

Levodopa/carbidopa solution for SC administration

Parkinson's Disease

Phase 1

Clinical Trials (1)

NCT01725802A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patients

Phase 1

LD/CD SC solution

Parkinson's Disease

Phase 1

Clinical Trials (1)

NCT02096601A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients

Phase 1

ND0611

Parkinson's Disease

Phase 1

Clinical Trials (1)

NCT01103011Safety, Tolerability and Pharmacokinetic Profile of Levodopa Administered With Continuous Administration of ND0611

Phase 1

ND0612

Parkinson's Disease

Phase 1

ND0801

Attention Deficit and Hyperactivity Disorder

Phase 1/2

Clinical Trials (1)

NCT01174355A Study of ND0801 in Attention Deficit/Hyperactivity Disorder (ADHD)

Phase 1/2

Saline

Parkinson's Disease

Phase 1/2

Clinical Trials (1)

NCT01229332A Safety, Tolerability and Pharmacokinetic Study of ND0611 on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Parkinson's Disease Patients

Phase 1/2

ND0612

Parkinson's Disease

Phase 2

Clinical Trials (1)

NCT02726386A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease

Phase 2

ND0612

Parkinson's Disease

Phase 2

Clinical Trials (1)

NCT02577523A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease

Phase 2

Levodopa and carbidopa

Parkinson's Disease

Phase 2

Clinical Trials (1)

NCT01883505A Phase 2a Study Followed to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients Receiving ND0612

Phase 2

ND0612 Solution for SC infusion

Parkinson's Disease

Phase 3

Clinical Trials (1)

NCT04006210Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations

Phase 3

ND0612

Parkinson's Disease

Phase 3

Clinical Trials (1)

NCT02782481A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations

Phase 3

ND0612

Parkinson

Phase 3

Clinical Trials (1)

NCT03462043A Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2021

Portfolio: 12 clinical trials

Top TAs: Neurology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Neurology

11 pipeline

Marketed

Pipeline